Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894343 · ClinicalTrials.gov registry record · Phase 1
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
A Phase 1 study of Parkinson's Disease, sponsored by MeiraGTx.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT05894343: Active Phase 1 study of Parkinson's Disease, sponsored by MeiraGTx.
NCT05894343 is a Phase 1 study of Parkinson's Disease that is active but no longer recruiting, run by MeiraGTx. The registered enrollment target is 13 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05894343, a Phase 1 study of Parkinson's Disease, is active but no longer recruiting, sponsored by MeiraGTx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
Conditions Studied
Interventions
- GENETIC AAV-GAD
Study Locations (6)
New York
- Weill Cornell Medicine - New York
- Columbia University Irving Medical Center - New York
Connecticut
- Yale University - New Haven
Michigan
- Henry Ford West Bloomfield Hospital - West Bloomfield
Pennsylvania
- Thomas Jefferson University - Philadelphia
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
What the registry record for NCT05894343 still lists
NCT05894343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which AAV-GAD is the first listed.
NCT05894343 lists 6 locations in 5 states (New York, Connecticut, Michigan).
Frequently Asked Questions
What is clinical trial NCT05894343 about?
NCT05894343 is a clinical study titled "Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease". The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
What is the current status of trial NCT05894343?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-05-19. Estimated completion is 2029-10.
What conditions does trial NCT05894343 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT05894343?
The interventions under investigation include: AAV-GAD (GENETIC).
Who is sponsoring clinical trial NCT05894343?
This trial is sponsored by MeiraGTx, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05894343 being conducted?
This trial has 6 study locations across Connecticut, Michigan, New York, Pennsylvania, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05894343's enrollment target sits among peer trials
13 139th of 158 higher than 17 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI